247 Papers
431 Citations
Sa A. Wang is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Medicine & Myeloid leukemia. The author has an hindex of 31, co-authored 197 publications. Previous affiliations of Sa A. Wang include University of Texas Health Science Center at Houston.
Chat about Author
Papers
International Consensus Classification of Myeloid Neoplasms and Acute Leukemia: Integrating Morphological, Clinical, and Genomic Data.
Daniel A. Arber,Attilio Orazi,Robert P. Hasserjian,Michael Horowitz,Katherine R. Calvo,Hans Michael Kvasnicka,Sa A. Wang,Adam Bagg,Tiziano Barbui,Susan Branford,Carlos E. Bueso-Ramos,Jorge E. Cortes,Paola Dal Cin,Courtney D. DiNardo,Hervé Dombret,Eric J. Duncavage,Benjamin L. Ebert,Elihu H. Estey,Fabio Facchetti,Kathryn Foucar,Naseema Gangat,Umberto Gianelli,Lucy A. Godley,Nicola Goekbuget,Jason Gotlib,Eva Hellström-Lindberg,Gabriela S. Hobbs,Roald Hoffmann,Elias Jabbour,Jean-Jacques Kiladjian,Richard A. Larson,Michelle M. Le Beau,Mignon L. Loh,Bob Löwenberg,Elizabeth Macintyre,Luca Malcovati,Charles G. Mullighan,Charlotte M. Niemeyer,Olatoyosi Odenike,Seishi Ogawa,Alberto Orfao,Elli Papaemmanuil,Francesco Passamonti,Kimmo Porkka,C H Pui,Jerald P. Radich,Andreas Reiter,María Rozman,Martina Rudelius,Michael R. Savona,Charles A. Schiffer,Annette Schmitt-Graeff,Akiko Shimamura,Jorge Sierra,Wendy Stock,Richard Stone,Martin S. Tallman,Juergen Thiele,Hwei-Fang Tien,Alexandar Tzankov,Alessandro M. Vannucchi,Paresh Vyas,Andrew H. Wei,Olga Weinberg,Agnieszka Wierzbowska,Mario Cazzola,Hartmut Döhner,Ayalew Tefferi +67 more
TL;DR: The authors, a group with expertise in the clinical, pathologic and genetic aspects of these disorders, developed the International Consensus Classification (ICC), aimed at facilitating diagnosis and prognostication of these neoplasms, improving treatment of affected patients, and allowing the design of innovative clinical trials.
Clonal evolution of acute myeloid leukemia revealed by high-throughput single-cell genomics.
Kiyomi Morita,Kiyomi Morita,Feng Wang,Katharina Jahn,Katharina Jahn,Tianyuan Hu,Tomoyuki Tanaka,Yuya Sasaki,Jack Kuipers,Jack Kuipers,Sanam Loghavi,Sa A. Wang,Yuanqing Yan,Ken Furudate,Ken Furudate,Jairo Matthews,Latasha Little,Curtis Gumbs,Jianhua Zhang,Xingzhi Song,Erika Thompson,Keyur P. Patel,Carlos E. Bueso-Ramos,Courtney D. DiNardo,Farhad Ravandi,Elias Jabbour,Michael Andreeff,Jorge E. Cortes,Kapil N. Bhalla,Guillermo Garcia-Manero,Hagop M. Kantarjian,Marina Konopleva,Daisuke Nakada,Nicholas Navin,Niko Beerenwinkel,Niko Beerenwinkel,P. Andrew Futreal,Koichi Takahashi +37 more
TL;DR: Using a single-cell DNA sequencing, the clonal architecture and mutational histories of 123 acute myeloid leukemia (AML) patients are reported, revealing cell-level mutation co-occurrence and enables reconstruction ofmutational histories characterized by linear and branching patterns of clonal evolution.
10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial.
Courtney D. DiNardo,Abhishek Maiti,Caitlin R. Rausch,Naveen Pemmaraju,Kiran Naqvi,Naval Daver,Tapan M. Kadia,Gautam Borthakur,Maro Ohanian,Yesid Alvarado,Ghayas C. Issa,Guillermo Montalban-Bravo,Nicholas J. Short,Musa Yilmaz,Prithviraj Bose,Elias Jabbour,Koichi Takahashi,Jan A. Burger,Guillermo Garcia-Manero,Nitin Jain,Steven M. Kornblau,Philip A. Thompson,Zeev Estrov,Lucia Masarova,Koji Sasaki,Srdan Verstovsek,Alessandra Ferrajoli,William Weirda,Sa A. Wang,Sergej Konoplev,Zhining Chen,Sherry Pierce,Jing Ning,Wei Qiao,Farhad Ravandi,Michael Andreeff,John S. Welch,Hagop M. Kantarjian,Marina Konopleva +38 more
TL;DR: It is hypothesized that venetoclax with 10-day decitabine could have improved activity in patients with newly diagnosed AML and those with relapsed or refractory AML, particularly in high-risk subgroups, as well as safety, overall survival, and duration of response.
276
Donor-specific anti-HLA Abs and graft failure in matched unrelated donor hematopoietic stem cell transplantation.
Stefan O. Ciurea,Peter F. Thall,Xuemei Wang,Sa A. Wang,Ying Hu,Pedro Cano,Fleur M. Aung,Gabriela Rondon,Jeffrey J. Molldrem,Martin Korbling,Elizabeth J. Shpall,Marcos de Lima,Richard E. Champlin,Marcelo Fernandez-Vina +13 more
TL;DR: The presence of anti-DPB1 DSAs is associated with graft failure in MUD hematopoietic stem cell transplantation in patients with matched unrelated donor (MUD) transplantation.
214
Atypical chronic myeloid leukemia is clinically distinct from unclassifiable myelodysplastic/myeloproliferative neoplasms
Sa A. Wang,Robert P. Hasserjian,Patricia S. Fox,Heesun J. Rogers,Julia T. Geyer,Devon Chabot-Richards,Elizabeth Weinzierl,Joseph Hatem,Jesse Jaso,Rashmi Kanagal-Shamanna,Francesco C. Stingo,Keyur P. Patel,Meenakshi Mehrotra,Carlos E. Bueso-Ramos,Ken H. Young,Courtney D. DiNardo,Srdan Verstovsek,Ramon V. Tiu,Adam Bagg,Eric D. Hsi,Daniel A. Arber,Kathryn Foucar,Raja Luthra,Attilio Orazi +23 more
TL;DR: Within MDS/MPN, the World Health Organization 2008 criteria for aCML identify a subgroup of patients with features clearly distinct from MDS /MPN-U, which is heterogeneous and patient risk can be further stratified by a number of clinicopathological parameters.
198